Once-daily tofacitinib formulation gets FDA clearance for RA
The Food and Drug Administration has approved a once-daily, extended-release tablet formulation of tofacitinib 11 mg, the drug’s manufacturer, Pfizer, announced.
The Janus kinase inhibitor, to be...
Source: Rheumatology News - Category: Rheumatology Source Type: research